Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 7/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 7/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764415 | 0.90 | NPC1 (0.35) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL24764431 | 0.89 | NPC1 (0.34) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL23696302 | 0.85 | HRH3 (0.40) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL23806152 | 0.83 | NPC1 (0.34) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL23560002 | 0.81 | CARM1 (0.44) | CARM1PRMT6HRH3TMEM97SIGMAR1 | |
| SCHEMBL21215040 | 0.80 | NPC1 (0.39) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL27378340 | 0.80 | NPC1 (0.41) | NPC1KDM4EMEN1KMT2AHTT | |
| SCHEMBL13676882 | 0.80 | NPC1 (0.36) | NPC1KDM4EMEN1KMT2AHTT | |
| SCHEMBL23945992 | 0.78 | NPC1 (0.40) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL13676876 | 0.78 | NPC1 (0.44) | NPC1KDM4EMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | NPC1 3895/4885CARM1 1340/4885PRMT6 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.